Saranas Inc., a Houston, TX-based medical device company with innovative technology for real-time detection and monitoring of internal bleeding during endovascular procedures, completed a $2.8m Series C funding round.
The company intends to use the proceeds to conduct a multicenter clinical pilot in the U.S. and to support U.S. commercialization plan.
Led by President and CEO Zaffer Syed, Saranas focuses on improving patient outcomes through early detection and monitoring of internal bleeding complications. The company’s Early Bird Bleed Monitoring System includes a vascular access sheath with embedded sensors that are designed to detect and monitor bleeding from a blood vessel accidentally injured during endovascular procedures, such as a transcatheter aortic valve replacement (TAVR), large bore hemodynamic support device placement, or other complex cardiovascular interventions, where the femoral artery or vein is used to obtain vascular access. The technology, invented at the Texas Heart Institute, enables physicians to mitigate downstream consequences by addressing bleeding complications immediately.
The financing follows the company’s recent De Novo application to the U.S. Food and Drug Administration (FDA) for the Early Bird™ Bleed Monitoring System.